Arrowhead Pharmaceuticals (ARWR) Expected to Announce Earnings on Monday

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is anticipated to release its Q2 2025 earnings data after the market closes on Monday, May 12th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $116.27 million for the quarter.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97). On average, analysts expect Arrowhead Pharmaceuticals to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ:ARWR opened at $13.01 on Friday. Arrowhead Pharmaceuticals has a 52 week low of $9.57 and a 52 week high of $30.41. The company has a fifty day simple moving average of $13.44 and a two-hundred day simple moving average of $17.96. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27. The company has a market cap of $1.79 billion, a price-to-earnings ratio of -2.52 and a beta of 0.89.

Insider Activity at Arrowhead Pharmaceuticals

In related news, CEO Christopher Richard Anzalone sold 51,425 shares of the firm’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $15.07, for a total transaction of $774,974.75. Following the transaction, the chief executive officer now owns 4,062,377 shares of the company’s stock, valued at $61,220,021.39. This trade represents a 1.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders sold a total of 275,880 shares of company stock valued at $4,034,037 over the last ninety days. Insiders own 4.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a report on Wednesday, February 12th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $42.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. Chardan Capital reiterated a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. Finally, B. Riley reissued a “buy” rating and issued a $38.00 price objective (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $41.44.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.